What Omega measures
Omega (Noren et al. 2008) is a disproportionality measure for drug-drug-event combination. It compares the observed number of reports listing two drugs and an adverse event with the number expected if the two drugs did not interact.
“No interaction” is defined by an additive model: the reporting rate of the event under both drugs is the background reporting rate plus the contribution attributable to each drug. This is the key difference from logistic regression, whose interaction term assumes multiplicative effects of separate drugs and misses well-established interactions such as cerivastatin with gemfibrozil.
The steps are:
- Count the reports in each of the four exposure strata: neither drug, D1 only, D2 only, both drugs.
- Compute the relative reporting rate of the event in each stratum:
f00,f10,f01,f11. - Estimate the expected rate under both drugs,
g11, fromf00,f10andf01only (eq. 16 of the paper). - Compute the expected count
E111 = g11 * n11.. - Compute the shrunk ratio
omega = log2((n111 + 0.5) / (E111 + 0.5))and its Gamma credibility interval.
A potential interaction is highlighted when omega_lower
is above 0.
Starting from counts
omega_from_counts() works with any data source. The
example below is the first case study of the paper: delayed bleeding
with itraconazole and oral contraceptives.
res <- omega_from_counts(
n111 = 10, n11. = 23, n1.1 = 10, n.11 = 19,
n1.. = 39, n.1. = 1489, n..1 = 39, n... = 5503
)
res[, .(f00, f10, f01, f11, g11, E111, omega, omega_lower, omega_upper)]
#> f00 f10 f01 f11 g11 E111 omega
#> <num> <num> <num> <num> <num> <num> <num>
#> 1: 0.005002501 0 0.006139154 0.4347826 0.006139154 0.1412005 4.03347
#> omega_lower omega_upper
#> <num> <num>
#> 1: 3.003327 4.790041Starting from a table of counts
omega_from_table() takes a data frame with one row per
drug1-drug2-event combination and one column per count
(n111, n11., n1.1,
n.11, n1.., n.1.,
n..1, n...). Other columns, such as labels,
are kept in the output.
counts <- data.frame(
drug1 = c("itraconazole", "drug A"),
drug2 = c("oral contraceptives", "drug B"),
event = c("delayed bleeding", "event X"),
n111 = c(10, 45), `n11.` = c(23, 250), `n1.1` = c(10, 120),
`n.11` = c(19, 85), `n1..` = c(39, 580), `n.1.` = c(1489, 420),
`n..1` = c(39, 340), `n...` = c(5503, 50000),
check.names = FALSE
)Groups of terms can be collapsed with lists, as in DiAna:
res <- omega_from_table(counts)
res[, .(drug1, drug2, event, f11, g11, omega, omega_lower, omega_upper)]Methodological choices to report
The counts come from your own data, and three choices made when building them change the results. State them in any publication:
- Drug roles. Which reported drugs count as exposure. At Uppsala Monitoring Centre only primary suspect, secondary suspect and interacting drugs count (Hult et al. 2020); reports where a drug is only concomitant then fall into the background stratum.
- Deduplication. Spontaneous reporting databases such as FAERS contain duplicate reports, which should be removed before counting.
-
Report universe. The total
n...defines the population of reports. Every other count must refer to this same set of reports.
Interpreting results
As recommended in the original paper, do not read Omega in isolation.
The columns f00, f10, f01 and
f11 show why a combination was highlighted. For example, a
large f10 means D1 alone already explains much of the
reporting.
Omega cannot be estimated when one of the four D1/D2 strata is empty
(for example, one drug is never reported without the other), or when
every report in the D1-only, D2-only or neither-drug stratum lists the
event (f10, f01 or f00 equal to
1). Such rows return NA for g11,
E111 and the Omega columns, with a warning that names the
affected rows and the reason.
References
Noren et al. 2007
Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Research Report. 2007;2007:6. Mathematical Statistics, Stockholm University.
Noren et al. 2008
Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27(16):3057-70.
Hult et al. 2020
Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43:775-85.
